The associate professor of neurology and neurologist at Duke University discussed the positive results of nipocalimab, a monoclonal antibody, in patients with myasthenia gravis.
Jeffrey Guptill, MD, MS, MHS
Advertisement
Associate Professor of Neurology, Duke University
Articles by Jeffrey Guptill, MD, MS, MHS
Advertisement
Latest Updated Articles
Nipocalimab Shows Promise as Myasthenia Gravis Treatment: Jeffrey Guptill, MD, MS, MHSPublished: April 23rd 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease
2
Analyzing Subgroup Data From the TRAILBLAZER-ALZ 2 Study of Donanemab: Brandy Matthews, MD
3
Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results
4
Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles
5
